Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > December 21, 2022
Daily News
December 21, 2022
- Japan Designates Antibiotics as Key Resources for Economic Security
December 21, 2022
- Livtencity Misses PIII Goal in 1st Line Use for HSCT CMV Infection
December 21, 2022
- Eisai to Divest US Fycompa Rights to Catalyst, Focus on Alzheimer’s R&D
December 21, 2022
- Nippon Shinyaku’s JAK2 Inhibitor Earns Orphan Designation in US
December 21, 2022
- Daiichi Sankyo’s Blood Cancer Drug Ezharmia Now Available
December 21, 2022
- Breyanzi Now Approved in Japan for 2nd-Line Large B-Cell Lymphoma: BMS
December 21, 2022
- Chugai CEO Questions Off-Year Price Cuts for On-Patent Meds
December 21, 2022
- Janssen Japan Employees Form Labor Union to Counter Closing of Positions
December 21, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…